29.03.2023
Innate Killer Summit 2023

Glycostem is going to participate Innate Killer Summit 2023, taken place on 28 - 30 March 2023 in San Diego, US.
Wednesday, 29 March 2023
14:30 Panel Discussion: Optimizing Innate Therapy in the Clinic
Kai Pinkernell, CMO, Glycostem

14:30 Panel Discussion: Sharing a Vision of the Future for Commercial Scale Manufacturing of Innate Immune Cells
Volker Huppert, CDO, Glycostem

15:15 Driving GMP Readiness with Scalable Manufacturing Platforms & Second Sourcing Strategies with GMP Materials
Volker Huppert, CDO, Glycostem

17:10 From Europe to the US: Sharing an Expert’s Guide to Regulatory Success in Europe, & Differences Identified in FDA Processes
Kai Pinkernell, CMO, Glycostem

31.01.2023
2nd Allogeneic Cell Therapies Summit Europe

Glycostem is going to attend the 2nd Allogeneic Cell Therapies Summit Europe in London.

31st January, 2023

16:30 GMT Maximising the Inherent Benefits of NK Cells to Effectively Target Solid Tumours

Presented by Jan Spanholtz, Chief Scientific Officer

• Capturing the intrinsic advantages of natural killer cells to infiltrate the solid tumour microenvironment
• Reflecting on NK cells anti GvHD functions to realise their full potential in allogeneic therapies
• Unlocking off-the-shelf NKs through effective and efficient large-scale manufacturing

1st February, 2023

12.30 GMT Optimising Manufacturing and Utilising Cryopreservation to Increase Allogeneic Product Shelf Life
Presented by Volker Huppert, Chief Development Officer

• Harnessing the potential of frozen products to reduce cost of goods and increase accessibility
• Optimising cryopreservation protocol to prevent decreases in quality, stability, and potency
• Employing frozen material to address scale and logistical challenges

18.01.2023
Advanced Therapies Week 2023

Glycostem Troels Jordansen is going to participate the Advanced Therapies Week 2023 in Miami, US from 18th to 20th Jan 2023.

Day 1 - January 18 2023
Think Locally, Source Globally: Are Your Products Region-Fixed or Trans-Continental?
Chairman to disucssion
3:30–5:00pm EST

Day 2 - January 19 2023
Storage and Preservation to Maintain High-Quality Raw Materials and Therapeutics
Presentation
1:30–3:00pm EST

Day 3 - January 20 2023
Disruptive and Novel Therapeutics for Oncology Indications
Presentation
9:00–10:30am EST

06.12.2022
Cell Therapy Manufacturing and Gene Therapy Congress 2022

Glycostem is going to present at the Cell Therapy Manufacturing and Gene Therapy Congress 2022 in Amsterdam.

6 Dec 2022, 11:35 (CET)

Scaling to Commercial Scale: Cord Blood Stem Cell Derived NK Cells

- presented by John Veluchamy, Senior Development Scientist

6 Dec 2022, 15:00 (CET)

Quality by Design for Cell Therapy Manufacturing

- presented by Valters Stelmanis, Regulatory Specialist


 

 

23.11.2022
European Immuno-Oncology Xchange

Glycostem CDO Volker Huppert is going to participate and lead a discussion at European Immuno-Oncology Xchange 2022 roundtable meeting on 23rd November 2022 in Zurich, Switzerland.

Topic: Cell Therapies going off-the-shelf: non-modified NK cells, CAR-NK cells, TCR-NK cells, combination therapies

Track: Next-Generation Therapies

Time: 16:15-17:15 (CET)

15.11.2022
Jefferies London Healthcare Conference 2022

Glycostem CEO Troels Jordansen is attending the Jefferies London Healthcare Conference from 15th to 16th Nov 2022 in London. The Jefferies London Healthcare Conference is the largest healthcare-dedicated conference in Europe.